Dr. Erik Holmlin
and Ashley, afternoon, good you, Thank everybody.
us transformed head joined Dr. of tech PerkinElmer worked was methods. by executives potential begin as has really of support quarter and momentum our came the for me significant Alka We Alka saying prior the Officer, publication key market first business that Let cytogenetics and the with progress Financial of we the semiconductor the the commercial how Vanadis. saw in Chris Chief and where from quarter had who addition are easing our of COVID-based previously she Genomics at successful career Most our pleased grew we as together. Medical in PerkinElmer, And traditional over significant returning up for of a third replacement more Chief Officer. indicators geographies Stewart, industries. two Chaubey, team to of with as We and our cytogenetics is areas evidence who Saphyr key leadership a more and presentation including in opened saw with restrictions. development, of Tesla,
insurance third-party strategic outline other potential and testing services and CLIA-based ingredients stock-based services Saphyr payers, grow Lineagen’s companies potential offering provide Finally, business on commercial transaction. has diagnostic the customers it has for services to services. governments. acquired in the to through our for to revenues of critical sales expand services path Lineagen data disorders, potential we to CLIA proprietary labs the CLIA a neurodevelopmental to total obtain need acquisition the to It pediatric from for The including the payment has who
model go-to-market the a reduced of start pursue and a commercial get a very easier rentals ever Bionano reagent the data instrument. price than since focus acquiring of a it our services, through has to combination that for Now, makes year to Saphyr been
karyotyping Initiative He in publications out patients X UC at significant X and flag the Upon country, number Children’s diagnoses just patients patients recall we Hospital. the of Our making you diagnosed, UC through further on Columbia base AML population. going at something leukemia and want goal the the of And from of has Oakland of a report clinical standard-of-care, able out that compared labs for as X candidate high-profile Medicine of this this adoption third that publication published also clinical been Dr. clinicians is mapping evaluation call XX the and we using some as Berkeley, came This to funded field. in that installed prestigious with number published biggest mapping us genetic paper the to to I’m testing with the XX worked estimate in actually State, nice authors on was to actually of And a XXXX. Bionano and institutes to done patients recently, XX of Probably to diagnose really the most Many we has papers of to to pathogenic is of driving the with Saphyrs Penn one the the of optical or tell in genome flagged the be acute for replaced and to University, grant. Saphyr that XX grow a myeloid Bionano amazing. year. in year the and this study. undiagnosed who patients, it’s also the published diagnostic study of that quarter, Overall, I test refer results University, this on based previously number to California milestone the be XXX number And been this could variants. line recommended to AML was that be Anderson highlight undiagnosed another around AML, out, and Saphyr other together Precision really Using It that is Columbia diagnosed. is and work or Mayo in this this this analysis, XX% is ever standard-of-care the disease that in who Bionano authors testing the of going was at evaluate significantly I the is will Saphyr scientists first from of Clinic, world. for is key patients. significantly The increase Kwok with the against compared the think XX mapping, of results Francisco. this were week the that a largest Bionano. the San optical those grown by Bionano of the amount really it’s total we share of methods. And Bionano to Pui flag we significance data step yield, were use the the all can happy another We in increase cancer of as working. last future. including group standard-of-care, patients. have and the paper this there help with want is landmark Augusta approach clinical relative That you technology demonstrating MD that incremental leukemia And year-to-date, believe evaluated the in really
presented Saphyr major of variation Bionano that’s year, at those what really the something virtually, data structural XXXX. is year-to-date, are been see conferences significant And about of increasing. number all course. national we awareness is the of XX% and publications up have that that that in And the this And papers human Bionano to is focused international across and compared globe
really felt off. the Bionano amount really our are the steps to us important like of field for and always have take to efforts that paying feels it’s data it in We increase
other for of let in turn -- business in the to key all the Now, some we’re areas. believe that momentum business, reflect other seeing significant the metrics of we significant which me
quarters quarter, we under contracts. reagent equal systems First sold those total customers to quarter, XX in rental nice of and rest believe, shipped of the continue That of the of that to momentum systems XXXX a over in of were combined, third expect year. to recovery XX of the which first all, we Saphyrs X two shipped were number this the the X is and reflecting, we
the completed the and the to with installations installation the Saphyrs quarter, installed that in XX. combined awaiting shipments number to these date brings are Saphyrs currently total number Now, XX, to of
cells the of number had array flow flow were X,XXX a nanochannel quarter cells shipped we sold. with that for record Next,
flow that unit a is the chip capacity. cell represents sample of Now, that human of measure the equivalent recall
three. have cells, Some of and our them have some chips flow two of
X,XXX third The of consumable So, sales XX% what we in of represents growth second the units flow growth sold and these quarter prior cells. measure over XX% progress quarter did we in cells and in the year, XXXX, over XXXX. cells flow customers of corresponds the this And for More data and quarter The and been being hear purchase more another with strong analyzed, potential really more will significant. samples customers here that flow quarter third progress Bionano is flow about. has cells. adoption the
that by perform Finally, even Keep wanted Data this strategy the market Saphyr projects in to number researchers solution a data, we for has or the purchase samples well commercial continued our believe work run also. we if continues a to of for Services as with And well. perform mind services our services to Bionano commercial lab Bionano couldn’t they who and rent instrument. And launched is development. essential
We to projects, XXXX, XXX the through third XXXX, ran just and XX the we had in run full-year of end far samples. and that projects, of XX quarter, compare the in a samples. total So when XXX we
which I on number the adoption and publications in are we see that see again, yield. incremental more of the is existing substantial Bionano improvement want to main growth in first and its in the more will drive those market as to succeed milestones clinical our turn, use. developed tests awareness So, the clinical lab, and by were in care, presentations To achieving we to available of being for and contribute effort utility. well diagnostic to and this of that samples labs that prerequisites, this talk offer processed publishing need as means to seeking about address more we Saphyr which adoption. as laboratory of what path, along develop data critical standard more more studies widespread in And to the also tests concordance result show Saphyr three multiple with in believe we
important The clinics the utilization to Saphyr-based second path in is, build test have to especially we third, And, clear these for the a need of development this labs and is for We for get United payers tests. States. and need and third-party laboratory developed reimbursed.
it. about Now, we’ve progress of these incredible all in and you I making want tell areas, been to
Penn On we’ve of data, led the XXX% including from that by Mayo, diagnostic as standard several of MD publications Radboud care discussed, Columbia that geneticists in University yield University of Augusta with cider the we’ve to others. Washington, University, show State, including with University, we of Anderson, been existing are this improvements come in Anderson, concordance in now, And describing the now able publications see publications concordance already Saphyr. consortium and adoption MD Netherlands;
we’re so We like to so that feel have come States. expect out, Columbia paper these that efforts And pleased we’re mass. the that represents best we to it in the United continue, because some build critical of the but has also we far data beginning
accreditation announced in or various laboratory this constitutional underway processes prerequisite solid disorder. have we Now, an of leukemia tests cause variations Saphyr LDTs key These genetic results in for there. are is of another Health development diseases work is detection the malignancies National cancer Augusta German us of genomics been for August. structural is types And and last underway that as United heme Netherlands. genetic LDT University the for based part for U.S. in the developed accreditation on and and meeting presented clinical at Similarly, System for quarter, developing Kingdom, in cancer, of the of consortium the Similar Belgium the their tumor. adoption.
as that about. will And CLIA We Bionano, partners we’ve develop LDTs are developed talked we CAP here as well. practices that labs a develop tests laboratory that commercial have and at service intend provider to certified accredited other
an obtaining a Saphyr And clinical so, lastly, jurisdictions the challenge effort developed world. the in the assays in are this around we And is available commercially acquired on regarding third-party good progress overcome U.S. on in of reimbursement, this we’re And acute mass critical most to that Lineagen making barrier.
that with working can vast the tests process, our license more CLIA in-house care. we control be of of their positioned and expertise when and standard officer to lot can with timelines. we Medical laboratory developed a together clinical partners, are Chaubey, they’re have the But, love we to our develop the With We upon leadership improve Chief certain now about very the supportive. Alka opportunity
to their the We intend and obtaining combination to for existing MolDX intend out Z and Lineagen’s obtaining contracts on Saphyr. third-party where expertise this And codes service, for of billing work coverage reimbursement so, coders CPT for certified path codes, codes. to based and PLA from of we leverage existing a use portfolio of appropriate, payer LDTs,
to paths these and which obtained, As Lineagen for get is path. to this enable established share follow intend labs, strategies them with reimbursement these we other will
other with and market. Lineagen Lineagen Saphyr. providers, Our of successful in commercialization them with I as is to key to service make available to compete clear such the is with those to Saphyr want be goal to overcoming intent barriers, that the reimbursement support adopting by not our but making solutions
few Finally, advancements our which our easier, upgrade and more and biggest them software Saphyr in say capabilities, Saphyr to cheaper significant the about technology. making I include want and faster ever importantly, a more use. Among things and capable, the is to to
weight for kit And study on really our new Saphyr received now enthusiastic, of ultra-high allows and in are the has simpler sales of of see expectations. amounts tumors. tumor comprehensive diseases, hard throughout from oncology, than system molecular analysis is remarkably inherited editing, newest conducting expanding. samples, the market which occurring rare that analysis effects during small in to much We DNA faster our systems the structural and all working achieve. have this to one other hurdles genomic easier DNA based Our removes detecting kind customers isolation to we’ve solid while for beat run of key the use isolation been our gene Applications been may that telling looking may responsible at that their feedback us variation genetic or be of that in users and is off-target CRISPR labs. variants our genome This be kit
we the we’re Saphyr genome and offers. metrics with that and have against the to so, And at believe to is comprehensive pleased like it, In or are that so Oxford hear we’re Saphyr. comparison Nanopore, it, about systems other capable get to especially and mention, to detection you which don’t read structural for tell analysis, of none very when it. we pleased to variation Not throughputs achievable compete performance, costs platforms, with the that necessary PacBio long speed cost the Saphyr, sequencing are
business. was now I our give update with to excited Chris will for And of so, the very you CFO, the this Chris? our overview new over an I on to financials. Stewart, turn that, And call
